Stocks Health care ENVB

NASDAQ · Health care

Enveric Biosciences, Inc. (ENVB)

It posted a net loss of $8.7M. At June 30, 2026 it held $8.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Enveric Biosciences, Inc. does

Enveric Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENVB.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Enveric Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.76 versus -$11.65.
2. August 14, 2026
   Quarterly results 8-K
3. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
4. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. August 13, 2026
   Passive stake changed SCHEDULE 13G/A
6. June 9, 2026
   Other event 8-K
7. June 9, 2026
   Securities offering prospectus 424B5
8. June 9, 2026
   Investor disclosure 8-K
9. June 1, 2026
   Employee stock plan registration S-8
10. May 29, 2026
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 3, 2026. Insider transactions on SEC

Insider trades

What the people running Enveric Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ENVB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Easton Jeff 1.4% (August 14, 2026); Ayrton Capital LLC 2.93% (August 13, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

8 insiders reported holding 611,961 shares in total, about $917.9K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ENVB

What does Enveric Biosciences, Inc. do?

Enveric Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENVB.

Is Enveric Biosciences, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $8.7M.

When did Enveric Biosciences, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare ENVB with

Compare ENVB with any company

Follow ENVB

Get an email when Enveric Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ENVB: get an email when it files

Where the numbers come from

Financial figures are the values Enveric Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.